Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04720209 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Taking AIM at Breast Cancer

StatusActive, Not Recruiting
PhaseNot applicable
Started2021-08-13
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Aug 31, 2026 → Oct 31, 2026
See other at-risk trials from Dana-Farber Cancer Institute

Amendment history

2026-09-30
Primary completion pushed: 2026-08-31 → 2026-10-31
Completion pushed: 2026-09-15 → 2028-12
2025-09-22
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v10
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2025-08-31→2026-08-31
Completion date2026-06-15→2026-09-15
Enrollment targetestimated 300→confirmed 102
Study sitesdetails revised at 2 of 2 sites
2025-07-07
Study Status v9
Primary completion date2025-06-15→2025-08-31
2025-01-27
3 amendments v6-v8
3 re-verifications since 2023-01-17, no change to tracked fields
2022-01-12
Study Status, Study Description, Arms and Interventions, Eligibility v5
Eligibility criteria-10 characters
Inclusion Criteria: Women newly diagnosed (Stage I-III)with breast cancer (all stages excluding stage IV), low grade disease positive for estrogen and progesterone receptors. Over the age of 18 years; children under the age of 18 will [...] rapy, participant must have received and completed treatment within the past 12 months. Speak English Is in breast cancer remission with no detect [...]
Show 4 earlier versions
2021-09-08
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v4
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2021-07→confirmed 2021-08-13
Study sitesdetails revised at 2 of 2 sites
2021-07-06
Study Status v3
Start date2021-06→2021-07
2021-05-12
Study Status v2
Start date2021-04→2021-06
2021-03-22
Study Status, Outcome Measures v1
Start date2021-02→2021-04
Primary endpoints1 to 3 entries
Decrease in adipose tissue levels of inflammation. Decrease in adipose tissue levels of inflammation.
2021-01-19
Original filing
The purpose of this research is to determine whether a 16-week exercise program for individuals with breast cancer and have completed treatment (i.e., surgery, chemotherapy, or radiation) for breast cancer will decrease inflammation in fat tissue.
Trial Details
NCT Number NCT04720209
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: National Cancer Institute (NCI)
Conditions Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Enrollment 102 participants
Start Date 2021-08-13
Primary Completion 2026-10-31 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-09-29